Foldax® announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine. Foldax was honored for its innovative Tria™ heart valve, the first biopolymer heart valve to receive FDA approval for a U.S. clinical trial.
Foldax has reinvented every aspect of the artificial heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime that address historical tradeoffs. The Tria heart valve is made with its proprietary LifePolymer™ biopolymer that, combined with an innovative valve design, is intended to eliminate calcification, withstand stresses and strains in the heart without failure, and restore patient quality of life without lifelong anticoagulant use.
Tria is also the first and only heart valve to be robotically manufactured, reducing variability and enabling high precision, repeatability and quality, while substantially improving the economics of heart
MORGAN HILL, CA / ACCESSWIRE / October 12, 2020 / Mitre Medical Corp. (“Mitre” or “company”) is an early-stage medical device company developing the Mitral Touch®, a less invasive and safer approach to treat functional mitral valve regurgitation (FMR) and remodel the left ventricle (LV). Mitre is pleased to announce that the company will be presenting at and participating in the U.S.-Japan cross-border event, MedTech Emerging Growth Companies 2020 Virtual Roadshow. Details about the event are as follows:
This year the MedTech Emerging Growth Companies 2020 Virtual Roadshow will introduce over 20 emerging U.S. medical technology companies to Japanese business, financial, academic, and government experts. The event is a collaboration between the Japan Society of Northern California and US-Japan Medtech Frontiers. The virtual conference will feature thematically grouped company presentations followed by online networking sessions with presenters.
“We are excited to follow-up on the success of last year’s conference. The